Myocardial Perfusion and Tissue Characterization with Photon-Counting CT in TAVI Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares photon-counting CT measurements of myocardial perfusion and extracellular volume with cardiac MRI in adults aged 60 and older who are being evaluated for transcatheter aortic valve implantation. It uses stress-induced perfusion imaging and extracellular volume quantification with PCCT to explore the technique’s accuracy and potential to reduce radiation and contrast exposure. The aim is to determine whether PCCT can provide reliable, MR-comparable information about myocardial perfusion and fibrosis in a routine TAVI work-up. Enrollment is limited to patients referred for TAVI planning at Karolinska University Hospital, with careful screening for contraindications to imaging contrast and other device-related exclusions. Findings will inform feasibility of PCCT as an alternative imaging modality in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients referred for TAVI planning CTA. Both sexes are eligible; equal sex distribution is not required. Age ≥ 60 years.

Exclusion Criteria:

\- Hemodynamic or rhythm related conditions: Systolic blood pressure \< 90 mmHg. Bradycardia: \< 45 beats/min. Persistent AV block II-III. Sick sinus syndrome. Prolonged QT interval. Atrial fibrillation. Severe heart failure: NYHA class IV.

Contrast or kidney relaterad factors: Previous allergic reaction to iodinated or gadolinium contrast or history of contrast induced nephropathy. Impaired renal function: eGFR \< 45 mL/min/1.73 m².

Implants or devices: Metallic implants or devices in the imaging area, e.g., pacemaker. Medication: Persantin (dipyridamole), Theophyllamine, Fevarin (fluvoxamine).

Where it's running

• Karolinska University Hospital
  Huddinge, Stockholm County, Sweden Recruiting

Study contacts

• Study coordinator: Yousuf Zakko, MD, PhD student
• Email: yousuf.zakko@regionstockholm.se
• Phone: +46 8-123 819 11

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardiac MRI-based prediction tool for outcomes in dilated cardiomyopathy

  This project will test whether adding multi-parameter stress perfusion cardiac MRI to routine clinical data can better predict which people with dilated cardiomyopathy will go on to develop heart failure, arrhythmias, hospitalizations, or death.

  Recruiting Shandong Provincial Hospital · Jinan, Shandong · NCT07527715

• Gallium-68 FAPI PET/CT to find cardiac fibrosis in heart failure

  This test will use a Gallium-68 FAPI PET/CT scan to see if it can detect active heart muscle fibrosis in adults with heart failure.

  Recruiting University of Coimbra · Coimbra, Coimbra District · NCT07296081

• Assessing heart tissue damage in patients with heart aneurysms after a heart attack

  This study is testing how heart tissue damage looks in patients with heart aneurysms after a heart attack using special imaging to see if it helps understand their condition better.

  Recruiting RenJi Hospital · Shanghai · NCT06994221

• Triple-drug therapy (ARNI + SGLT2 inhibitor + MRA) for advanced HFpEF

  This study will test whether giving an ARNI together with an SGLT2 inhibitor and an MRA helps people with advanced HFpEF stay healthier over 52 weeks compared with individualized medical therapy.

  Recruiting Phase 2 National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Moscow · NCT06655480

• High-relaxivity Elucirem contrast for cardiac MRI to detect myocardial scar

  This test will see if a half dose of Elucirem (gadopiclenol) can detect heart muscle scar as well as a double dose of Dotarem in adults who previously had cardiac MRI.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland and 1 other locations · NCT05954559

• Gene therapy for heart issues in Friedreich's ataxia

  This study is testing a new gene therapy for heart problems in people with Friedreich's ataxia to see if it is safe and helps improve their heart function.

  Recruiting Phase 1 Weill Medical College of Cornell University · New York, New York · NCT05302271

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.